The proposed HIRE Act 2025 in the US would impose a 25% tax on payments to foreign workers for services used within America, ...
A piece of US legislation from 2024 that aimed to curb American companies’ ties to certain Chinese biotechs has made a comeback – and Indian contract drug manufacturers are primed to benefit from it.
The revived US Biosecure Act aims to curb Chinese biotech ties, creating major opportunities for Indian pharma and biotech firms in global supply chains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback